section name header

10 Second Take

Saw palmetto fruits, once used as food, are benign. Clinical trial evidence supports its efficacy for treating benign prostatic hyperplasia (BPH); prostate-specific antigen (PSA) is not affected.

Basics

[LFODPKM ] Letter Key

Latin Namenavigator

Serenoa repens [Bartr.] Small, syn. S. serrulata [Mich.] Hook f., Sabal serrulata [Mich.] Nuttall ex Schult.

Familynavigator

Palmae/Arecaceae

Other Common Namesnavigator

Dwarf American palm

Descriptionnavigator

Part Usednavigator

Dried ripe fruit

Known Active Constituentsnavigator

Mechanism/Pharmacokineticsnavigator


[Outline]

Evidence

[CAO ] Letter Key

Clinical Trialsnavigator

Animal/In Vitronavigator

Other Claimed Benefits/Actionsnavigator


[Outline]

Risks

[AP ] Letter Key

Adverse Reactionsnavigator

Pregnancy/Lactationnavigator


[Outline]

Dose

Common Dosage Forms

Common Questions and Answers


Q: Does saw palmetto affect tests for prostate specific antigen?navigator

A: No. PSA levels were assessed in at least three trials (11,14,15), none of which found an effect of saw palmetto on PSA.

Q: How does saw palmetto compare to drugs used to treat BPH?navigator

A: No trials have compared saw palmetto to terazosin to date, but the herb has been compared with two other alpha-blockers and finasteride. A 3-week study in 63 patients with BPH compared saw palmetto (160 mg b.i.d.) to alfuzosin (2.5 mg t.i.d.) (16). Clinical symptoms, urinary flow rates, and residual urinary volume by transabdominal ultrasound were assessed. Both treatments significantly improved nocturia, daytime frequency, peak flow rates, mean flow rates and residual urinary volume, with no significant difference between groups. However, alfuzosin was significantly more effective than saw palmetto for total symptom score on Boyarsky’s scale, visual analog scale and on overall clinical impression.

A 12-week trial compared Permixon (2 tablets daily) to prazosin (4 mg/day) in 42 men; peak flow increased from 9.75 ± 7.29 mL/s to 11.25 ± 8.77 mL/s in the Permixon group, compared with 10.36 ± 7.86 mL/s to 10.83 ± 11.07 mL/s in the prazosin group. Episodes of nocturia decreased from 2.5 ± 1.17 to 2.3 ± 1.39 in the Permixon group compared with a change from 2.1 ± 1.61 to 1.7 ± 1.76 in the prazosin group (17). Results apparently favored prazosin, but no statistical analysis was done (4).

A double-blind randomized study compared 5 mg finasteride to Permixon 320 mg for 6 months in 1,098 men with moderate BPH (14). Permixon and finasteride were equivalent in decreasing the International Prostate Symptom Score, improving quality of life, and increasing peak urinary flow. Finasteride decreased prostate volume and serum PSA levels, whereas Permixon had no effect on either. Permixon was less likely to cause complaints of decreased libido and impotence.

Q: What other uses are there for saw palmetto?navigator

A: Saw palmetto stems were once used as a starch, and the fruits were an important food for pre-Colombian people and Creek immigrants in Florida, although they are not uniformly popular. One correspondent described the taste as "rotten cheese steeped in tobacco" (1). Fibers have been used to make scrubbing brushes, roots were used for paper manufacture, leaves and stem fibers have been used as upholstery fill, and the stem was once used as a cork substitute. The fibers are also widely used in Seminole and Miccosukee crafts. Leaves are sometimes used as roof thatch.

References

  1. Bennett BC, Hicklin JR. Uses of saw palmetto (Serenoa repens, Arecaceae) in Florida. Econ Botany 1998;52;381–393.
  2. Awang DVC. Saw palmetto, African prune and stinging nettle for benign prostatic hyperplasia (BPH). Can Pharm J 1997;37–44, 62.
  3. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996;48:12–20.
  4. Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379–395.
  5. Rhodes L, Primka RL, Berman C. Comparison of finasteride (Proscar®), a 5alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5alpha reductase inhibition. Prostate 1993;22:43–51.
  6. Sultan C, Terraza A, Devillier et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens b" in human foreskin fibroblasts. J Steroid Biochem 1984;20:515–519.
  7. Strauch G, Perles P, Vergult G. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247–252.
  8. Goepel M, Hecker U, Krege S et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha-1 adrenoreceptors in vitro. Prostate 1999;38:208–215.
  9. Wilt TJ, Ishani A, Stark G et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604–1609.
  10. Boyle P, Robertson C, Lowe F et al. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533–539.
  11. Marks LS, Partin AW, Epstein JI et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451–1456.
  12. Paubert-Braquet M, Richardson FO, Servent-Saez N et al. Effect of Serenoa repens extract on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34:171–179.
  13. Baker VA, Hepburn PA, Kennedy SJ et al. Safety evaluation of phytosterol esters. Part 1. Assessment of oestrogenicity using a combination of in vivo and in vitro assays. Food Chem Toxicol 1999;37:13–22.
  14. Carraro J-C, Raynaud J-P, Hock G et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231–240.
  15. Gerber GS, Bales GT, Chodak GW et al. Serenoa repens (saw palmetto) in men with benign prostatic hyperplasia (BPH): effects on voiding symptoms, urodynamic parameters and serum prostate specific antigen (PSA). J Urol 157:331(abst no 1291).
  16. Grasso M, Montesano A, Buonaguidi A et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp de Urol 1995;48:97–103.
  17. Adriazola Semino M, Lozano OJ, Garcia CE et al. Symptomatic treatment of benign hypertrophy of the prostate: comparative study of prazosin and Serenoa repens. Arch Esp Urol 1992;45:211–213.